Introduction {#S1}
============

Pulmonary hypertension (PH) is a common complicated disorder characterized by a rest mean pulmonary artery pressure of \>25 mm Hg. The World Health Organization (WHO) categorized PH into 5 categories according to common clinical parameters, potential pathology, pathophysiology, etiology, and therapies. Specifically, pulmonary arterial hypertension (PAH) belongs to the WHO Group I characterized by an increased vasomotor tone, vascular resistance from abnormal narrowing, and precapillary vasculature remolding associated with abnormalities of proliferation and apoptosis ([@B34]; [@B30]; [@B44]). Although available therapies for PAH are commonly designed to revise the elevated vascular tone and vascular remodeling, the outcomes of these therapies are still not satisfied in clinic ([@B22]). Therefore, a better understanding of the pathology of PAH is necessary to develop some useful therapies to manage this syndrome ([@B16]).

Hypoxia is one of the most important causes for vascular remodeling during the parthenogenesis of PAH ([@B23]; [@B40]). Chronic alveolar hypoxia is likely to promote pulmonary vasoconstriction and vessel remolding ([@B33]; [@B15]). Hypoxia inducible factors (HIFs) are a class of transcriptional factors that respond to hypoxia ([@B39]). Among these, *HIF-1*α has been identified to play a critical role in the regulation of PAH ([@B43]). Roger A et al. have demonstrated that *HIF-1*α is crucial for the hypoxia-induced mitogenic factor induced PH ([@B12]). [@B17] have documented that *KLF5* mediates hypoxia-induced vascular remodeling via *HIF-1*α. Meanwhile, inhibiting the expression of HIF-1α alleviates hypoxia-induced PH ([@B41]). Moreover, *Pyk2* contributes to hypoxia-induced PH via activating *HIF-1*α ([@B14]). [@B11] have also reported that S*UMO-1* can interact with *HIF-1*α to regulate sumoylation of *HIF-1*α responding to hypoxia. Despite these findings, the mechanism of *HIF-1*α in PH is still not clearly understood.

Long non-coding RNAs (lncRNA) are a class of transcriptomes with non-protein coding ability and length ≥200 nt ([@B36]), and have been identified as playing critical roles in the regulation of cell activities, including metabolism, proliferation, apoptosis, metastasis, and invasion ([@B20]; [@B35]; [@B8]; [@B27]). Recently, [@B3] have reported that lncRNA *MEGs* serves as an emerging factor in hypoxia-induced PH. [@B48] have observed that polymorphism re619586A \>G in lncRNA *MALAT1* contributes to PAH susceptibility in Chinese people. [@B47] have identified that lncRNA *BCYRN1* promotes the proliferation and migration of rat airway smooth muscle cells in asthma via elevating the expression of *TRPC1*. All of these findings indicate that lncRNAs also play critical roles in the regulation of PAH, but evidence in this area is still rarely reported.

To further reveal the pathogenesis of PAH, the effect of *HIF-1*α on PAH was identified. Meanwhile, CoCl~2~ treated cells and their corresponding controls were sequenced and analyzed using a bioinformatics method in pulmonary artery smooth muscle cells to further explore the genes and lncRNAs involved in hypoxia-induced PAH pathogenesis, providing some new insights in the understanding and treatment of PAH.

Materials and Methods {#S2}
=====================

Ethics Approval and Consent to Participate {#S2.SS1}
------------------------------------------

This article does not contain any studies with human participants or animals performed by any of the authors.

Cell Culture and Treatment {#S2.SS2}
--------------------------

In the current study, two cell lines, human pulmonary artery smooth muscle cells (HPASMCs), and human embryonic kidney cells 293T, were used for the following investigations. 293T cell lines were maintained in Dulbecco's modified eagle medium (DMEM, Gibco, Grand Island, NY, United States) supplemented with 10% of fetal bovine serum (FBS) and Penicillin/Streptomycin at 37°C with 5% CO~2~. HPASMCs were maintained in DMEM supplemented with 15% of FBS at 37°C with 5% CO~2~ ([@B18]).

CCK-8 Assay {#S2.SS3}
-----------

The proliferation of cells treated with different concentrations of CoCl~2~ were determined using a CCK-8 kit (DOJINDO, Japan). Briefly, HPASMCs were seeded in 96-well plate with 2 × 10^4^ for each well overnight. After adherence, cells were separately treated with 50, 100, or 200 μM CoCl~2~ for 24 and 48 h. Then, 10 μl CCK-8 solution was added in each well and the cells were cultured at 37°C for 2 h. Following this, the optical density (OD) of each well at 450 nm was measured using an Enzyme-linked immunoassay instrument (TECAN Infinite M100 PRO, CA, United States). Each treatment was repeated six times, and the mean value of OD was calculated as the final result.

5-Bromo-Deoxyuridine (BrdU) Assay {#S2.SS4}
---------------------------------

The BrdU assay was performed according to the protocol of the BrdU Cell Proliferation Assay Kit (Frdbio, China). Briefly, BrdU labeling solution was added to each well for 4 h. After cells were fixed and DNA denatured, 100 μl BrdU detection antibody were added under a condition of mild vibrating at room temperature for 1 h. Then, the anti- BrdU HRP conjugated antibody was added to the cultures and incubated for 1 h at room temperature. After three washing steps the bound peroxidase was detected by subsequent substrate reaction. This reaction was stopped by adding 100 μl stop buffer and quantified by measuring the optical density (OD) at a wavelength of 450 nm on a microplate reader (BioTek, United States).

Apoptosis {#S2.SS5}
---------

Apoptosis for HPASMCs with CoCl~2~ treatment was also determined in the present study. Briefly, HPASMCs were seeded in six-well plate with 4 × 10^5^ for each well overnight followed by the treatment with 200 μM CoCl~2~ and DMSO for 48 h. After that, cells were trypsinized and centrifuged at 1500 rpm for 6 min. The cell sediment was washed with phosphate buffer solution and re-suspended with 1 × Binding Buffer. Then, 100 μl cell-binding buffer was collected, and incubated with 5 μl FITC-Annexin V (BD, United States) and 5 μl PI (50 μg/ml) at room temperature in a dark place. Meanwhile, unstaining, single Annexin-V staining, and single PI staining were also performed to minimize error during these procedures. After incubation, solution was mixed with 400 μl 1 × Binding Buffer and measured using a flow cytometry. Each experiment was performed three times, and the mean value was computed.

Sequencing and Bioinformatics Analysis {#S2.SS6}
--------------------------------------

With a confluency of 70∼80%, HPASMCs were treated with 200 μM CoCl~2~ for 48 h, and DMSO were used as the control treatment. Each treatment was performed three times. Then, total RNA of cell samples was isolated and sequenced on the Hiseq4000 sequencing platform (Illumina). Based on the recorded data, lower quality of reads and beads were filtered out, and the clean reads were calculated. Following this, clean reads were mapped to human reference genome 19 using tophat ([@B38]). According to the known genes and lncRNA annotation provided by gencode v24 ([@B10]), fpkm and read count of sequencing genes were obtained using stringtie ([@B28]), and differentially expressed genes (DEGs) and differentially expressed lncRNAs (DELs) were screened using LIMMA in R ([@B31]) with the thresholds of \|log2 Fold change (FC)\| \>1 and false discovery rate (FDR) \<0.05. Based on the Spearman rank correlation coefficient, targets of lncRNAs were screened from DEGs with the thresholds of *P* \< 0.05 and coefficient \>0.8, and the lncRNA-target regulatory network was visualized using Cytoscape ([@B32]). Furthermore, Gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses of DEGs, as well as the targets of lncRNAs, were also carried out using clusterprofile package in R ([@B42]). Finally, protein-protein interactions (PPIs) among DEGs were predicted using STRING ([@B7]), and PPI network was visualized using Cytoscape.

Quantitative Real-Time PCR (RT-PCR) {#S2.SS7}
-----------------------------------

Total RNA was isolated using Trizol Regent (Invitrogen, Carlsbad, CA, United States), according to the manufacture's protocol. Then, RNA concentration was quantified using NanoDrop 2000 (Thermo, Wilmington, DE, United States), and 0.5 μg total RNA was reversed to cDNA using 5 × primeScript RT Master Mix (Takara, Dalian, China), according to its instructions. Subsequently, gene expression was measured using SYBR Premix EX Taq (2 ×) with the following procedure: 50°C for 3 min, 95°C for 3 min, and 40 cycles of 95°C for 10 s and 60°C for 30 s. The relevant target gene expression levels were calculated with the 2-ΔΔCT method ([@B21]). Primers of genes were tabulated in [Table 1](#T1){ref-type="table"}.

###### 

Primers for real-time PCR.

  Primers        Forward                          Reverse
  -------------- -------------------------------- -------------------------------
  HIF-1α         5′-GCCCTAACGTGTT ATCTGTCG-3′     5′-TTGCTCCATT CCATTCTGTTC-3′
  PFKP           5′-TACTTCATCTACGAG GGCTACCA-3′   5′-AATGATCGTCCCG CCCACTT-3′
  VEGFA          5′-GCCTTGCCTTGCT GCTCTAC-3′      5′-CTCGATTGGATGG CAGTAGC-3′
  LDHA           5′-GTCAGCAAGAGGGA GAAAGC-3′      5′-TCCAAGCCACGTAG GTCAAG-3′
  HIST1H1B       5′-CTGGTGCTTCTG GCTCCTTTAA-3′    5′-CGCCTTCTTCGG AGTCTTCTT-3′
  HIST2H4A       5′-ACAACATTCAGG GCATCACCA-3′     5′-CTCCAGGAACACCT TCAGCACA-3′
  MIR100HG       5′-ACATTGGTCCAC TTGACACT-3′      5′-CAACTTGATGGCAA ACTCCC-3′
  RP11-166D19    5′-TGCCAGTCAGC CTTTGTAGT-3′      5′-AGAGTTTGGGAGC AGAGGGA-3′
  AP001065.15    5′-CCAGGCAAGAAC CCAGGATA-3′      5′-ACACTCAGGCAG GCTCCCAC-3′
  TSPEAR-AS2     5′-GGACATCACTCGC CTTCAGA-3′      5′-CTAACGAATGAGCT GGTGGG-3′
  DYX1C1-CCPG1   5′-CTCGCTCTGTTG GCAGTATTA-3′     5′-TCATTGCTCTT CGTGCCTCA-3′
  LINC00951      5′-CAGCCCTTTCCACCT ACTACAT-3′    5′-GCATGTGGGTGTTG GTGAGA-3′
  β-actin        5′-GGCCGAGGAC TTTGATTGCA-3′      5′-GGGACTTCCTGTT AACAACGCA-3′

Western Blotting {#S2.SS8}
----------------

Cells were lysed in RIPA lysis buffer (Beyotime, China) coupled with PMSF (Beyotime) at a final concentration of 1 mM, followed by the determination of protein concentration using the BCA Protein Assay Kit (Thermo). Protein from each sample was separated by 10% SDS-polyacrylamide gel and transferred onto polyvinylidene difluoride (PVDF) membranes (Millipore). Five percent of skim milk (BD) was used to block the non-specific binding for 1--2 h at 37°C, and then incubated with anti-LDHA (1:5000, Abcam), anti-VEGFA (1:10000, Abcam), and anti-PFKP (1:2000, Abcam) primary antibody at 4°C overnight. The membrane was washed with PBST buffer and then incubated with Goat Anti-Rabbit IgG (H + L) (1:10000, Jackson) for 2 h at 37°C. After washing with PBST buffer for six times, the membrane was exposed to enhanced chemiluminescence (ECL) reagents (Share-bio) and the Millipore ECL system, and then gray scanning was performed using TanonImage (4600, Tanon).

Statistical Methods {#S2.SS9}
-------------------

In the current study, statistical analyses were performed using GraphPad prism (GraphPad software, San Diego, CA, United States). Continuous variables were presented with mean ± standard error of mean. Comparisons between groups were estimated using *t*-test, and *P* \< 0.05 was considered statistically significant.

Results {#S3}
=======

CoCl~2~ Increased the Proliferation of HPASMC {#S3.SS1}
---------------------------------------------

After being treated with CoCl~2~, the expression of HIF-1α in HPASMCs was determined using RT-PCR, and the results showed that the expression levels of HIF-1α were significantly increased in HPASMCs with a dose-dependent manner at 24 and 48 h ([Figure 1A](#F1){ref-type="fig"}). Then, 200 μM CoCl~2~ treatment for 48 h was utilized for the following investigation. Subsequently, the proliferation and apoptosis of HPASMCs were measured. The results showed that the proliferation of HPASMCs was significantly increased after treatment with 200 μM CoCl~2~ both determined by CCK-8 assay ([Figure 1B](#F1){ref-type="fig"}) and by BrdU assay ([Figure 1C](#F1){ref-type="fig"}), but no significant variation was identified in apoptosis after being treated with CoCl~2~, compared with the control group ([Figure 1D](#F1){ref-type="fig"}).

![Effect of CoCl~2~ on HPASMCs. **(A)**, expression of HIF-1α in HPASMCs after being treated with CoCl~2~ at 24 h and 48 h; **(B)**, proliferation of HPASMCs after treatment with CoCl~2~ determined by CCK-8 assay; **(C)**, proliferation of HPASMCs after being treated with CoCl~2~ determined by CCK-8 assay BrdU assay, and **(D)**, apoptosis of HPASMCs after being treated with CoCl~2~. \**P* \< 0.05 indicates that there is significantly different when compared with control groups. \*\**P* \< 0.01 and \*\*\**P* \< 0.001.](fgene-11-00232-g001){#F1}

DEGs/lncRNA Screening and Functional Enrichment Analyses {#S3.SS2}
--------------------------------------------------------

In total, 360 DEGs (178 up-regulated genes and 182 down-regulated genes) and 57 DELs (21 up-regulated lncRNAs and 36 down-regulated lncRNAs) were identified in CoCl~2~-treated HPASMCs compared with the controls. Heatmaps of DEGs and DELs are presented in [Figures 2A,B](#F2){ref-type="fig"}. Moreover, GO enrichment analysis showed that the up-regulated DEGs were significantly enriched in the biological process (BP) terms of cellular response to hypoxia (*P* = 3.78 × 10^--09^), monosaccharide metabolic process (*P* = 4.61 × 10^--09^), cellular response to oxygen levels (*P* = 4.61 × 10^--09^), glycolytic process (*P* = 6.50 × 10^--09^), and pyruvate metabolic process (*P* = 8.32 × 10^--09^); and the down-regulated DEGs were closely associated with the BP terms of extracellular matrix organization (*P* = 2.42 × 10^--06^), collagen catabolic process (*P* = 3.30 × 10^--05^), multicellular organismal catabolic process (*P* = 3.79 × 10^--05^), extracellular matrix disassembly (*P* = 3.79 × 10^--05^), and single-substrate adhesion (*P* = 1.45 × 10^--04^) ([Table 2](#T2){ref-type="table"}). Meanwhile, KEGG enrichment analysis indicated that the up-regulated DEGs were primarily enriched in the pathways of Glycolysis/Gluconeogenesis (*P* = 6.98 × 10^--07^), Fructose and mannose metabolism (*P* = 2.16 × 10^--07^), and metabolic pathways (*P* = 2.28 × 10^--03^); the down-regulated DEGs played essential roles in the pathways of systemic lupus erythematosus (*P* = 1.06 × 10^--15^), ECM-receptor interaction (*P* = 3.82 × 10^--06^), Amoebiasis (*P* = 1.13 × 10^--05^), and focal adhesion (*P* = 4.91 × 10^--04^) ([Table 2](#T2){ref-type="table"}).

![Heatmaps for DEGs and DELs. **(A)**, heatmap for DEGs; and **(B)**, heatmap for DELs. DEGs, differentially expressed genes; and DELs, differentially expressed long non-coding RNAs.](fgene-11-00232-g002){#F2}

###### 

Top 5 GO-BP terms enriched by the up- and down-regulated DEGs.

  Terms                                        Count   *P* value          GeneSymbols
  -------------------------------------------- ------- ------------------ ----------------------------------------------------------
  **A: Go functional enrichment**                                         
  ***Up-regulated DEGs***                                                 
  Cellular response to hypoxia                 12      3.78 × 10^--09^    *NDRG1*, *EGLN3*, *FAM162A*, *HMOX1*, *PDK1*, *VEGFA*...
  Monosaccharide metabolic process             17      4.61 × 10^--09^    *ENO2*, *ALDOC*, *G6PD*, *GBE1*, *VEGFA*...
  Cellular response to oxygen levels           12      4.61 × 10^--09^    *NDRG1*, *EGLN3*, *FAM162A*, *HMOX1*, *PDK1 VEGFA*....
  Glycolytic process                           10      6.50 × 10^--09^    *ENO2*, *ALDOC*, *HK2*, *LDHA*, *PFKFB3*...
  ***Down-regulated DEGs***                                               
  Extracellular matrix organization            14      2.42 × 10^--06^    *COL1A1*, *COL2A1*, *COL3A1*, *COL26A1*,*THBS1*.
  Extracellular structure organization         14      2.42 × 10^--06^    *COL1A1*, *COL2A1*, *COL3A1*, *COL26A1*,*THBS1*.
  Collagen catabolic process                   7       3.30 × 10^--05^    *COL1A1*, *COL2A1*, *COL3A1*, *COL26A1*, *ADAMTS14*.
  Multicellular organismal catabolic process   7       3.79 × 10^--05^    *COL1A1*, *COL2A1*, *COL3A1*, *COL26A1*, *ADAMTS14*.
  Extracellular matrix disassembly             8       3.79 × 10^--05^    *COL1A1*, *COL2A1*, *COL3A1*, *COL26A1*, *LAMC2*.
                                                                          
  **B: KEGG functional enrichment**                                       
                                                                          
  ***Up-regulated DEGs***                                                 
  Glycolysis/Gluconeogenesis                   8       6.98 × 10^--075^   *HKDC1*, *ALDOC*, *PGM1*, *HK2*, *ENO2*, *PFKP.*
  Fructose and mannose metabolism              6       2.16 × 10^--06^    *HKDC1*, *ALDOC*, *PFKFB4*, *HK2*, *PFKFB3*, *PFKP*
  Metabolic pathways                           21      2.28 × 10^--03^    *HKDC1*, *GCNT3*, *TYRP1*, *GCLM*, *AK4*.
  ***Down-regulated DEGs***                                               
  Systemic lupus erythematosus                 16      1.06 × 10^--15^    *HIST1H2AE*, *HIST1H3C*, *HIST2H3A*, *HIST2H4A*...
  ECM-receptor interaction                     7       3.82 × 10^--06^    *LAMA4*, *THBS1*, *COL1A1*, *COL3A1*, *COL2A1*.
  Amoebiasis                                   7       1.13 × 10^--05^    *LAMA4*, *COL1A1*, *COL3A1*, *COL2A1*, *LAMC2*.
  Focal adhesion                               7       4.91 × 10^--04^    *LAMA4*, *THBS1*, *COL1A1*, *COL3A1*, *COL2A1*.

GO, gene ontology; BP, biological process; DEG, differentially expressed genes.

Constructions of PPI Network and lncRNA-Target Network {#S3.SS3}
------------------------------------------------------

Based on the selection criteria, PPI among DEGs encoded proteins were predicted and visualized using Cytoscape ([Figure 3](#F3){ref-type="fig"}). The top 10 nodes involved in this network were: *VEGFA* (degree = 21), *LDHA* (degree = 20), *HIST1H1B* (degree = 17), *HIST2H4B* (degree = 16), *HIST2H4A* (degree = 16), *HK2* (degree = 15), *HIST1H2AI* (degree = 15), *HIST1H2AE* (degree = 15), *PFKP* (degree = 14), and *HIST3H2BB* (degree = 14).

![PPI network for DEGs. Red circle represents the up-regulated DEGs and green circle represents the down-regulated DEGs. Nodes size was positively correlated with node degree. PPI, protein-protein interaction network; and DEGs, differentially expressed genes.](fgene-11-00232-g003){#F3}

Meanwhile, 286 targets by 57 lncRNAs were also selected from DEGs, and the lncRNA-target network was constructed with 343 nodes (proteins) and 2855 edges (PPI pairs) ([Figure 4](#F4){ref-type="fig"}). The top 10 nodes with highest degrees were: *RP11-486B10.3* (degree = 127), *RP11-449P15.2* (degree = 97), *RP11-229P13.19* (degree = 93), *AF131216.5* (degree = 93), *LINC00618* (degree = 93), *RP11-429D19.*1 (degree = 93), *CHRM3-AS1* (degree = 93), *CH507-42P11.3* (degree = 88), *AP001056.1* (degree = 88), and *RP11-488C13.5* (degree = 85). Notably, *LDHA*, *PFKP*, and *VEGFA* as hub genes in PPI network presented a close correlation with miR-100HG and *TSPEA-AS2* in lncRNA-target network ([Table 3](#T3){ref-type="table"}).

![lncRNA-target network. Red circle represents the up-regulated DEGs, green circle represents the down-regulated DEGs, and diamond represents lncRNA. lncRNA, long non-coding RNA; and DEGs, differentially expressed genes.](fgene-11-00232-g004){#F4}

###### 

The interaction pairs of top 10 hub genes in PPI network and lncRNAs.

  Tagrets       LncRNA           *P*-value
  ------------- ---------------- -----------
  *VEGFA*       MIR100HG         0.017
                TSPEAR-AS2       0.017
  *LDHA*        MIR100HG         0.017
                TSPEAR-AS2       0.017
                LINC01397        0.005
                TSPEAR-AS1       0.003
                AC083843.1       0.003
                DYX1C1-CCPG1     0.017
                AC003092.1       0.017
                AP001065.15      0.003
                MALAT1           0.017
                RP4-737E23.5     0.003
                AL591893.1       0.008
                LUCAT1           0.017
                RP11-359D14.3    0.008
                RP11-166D19.1    0.003
  *PFKP*        MIR100HG         0.017
                TSPEAR-AS2       0.017
  *HIST1H1B*    XXbac-B33L19.3   0.017
                CHRM3-AS1        0.005
                RP11-179B2.2     0.017
                RP11-449P15.2    0.003
                AP001056.1       0.008
                RP11-488C13.5    0.017
                CH507-42P11.3    0.008
                LINC00618        0.005
                RP11-826N14.1    0.000
                AF131216.5       0.005
                RP11-229P13.19   0.005
                RP11-486B10.3    0.008
                CTB-113P19.3     0.008
                RP11-429D19.1    0.005
  *HIST2H4B*    FOXN3-AS1        0.005
                DNAH17-AS1       0.005
                RP11-404P21.5    0.008
                RP11-362F19.1    0.005
                RP11-179B2.2     0.017
                CTD-2184D3.7     0.005
                ERVK-28          0.000
                RP11-488C13.5    0.017
                AJ011932.1       0.000
                RP11-665C16.5    0.005
                RP1-90G24.10     0.008
                RP1-283K11.3     0.000
                RP11-486B10.3    0.008
  *HIST2H4A*    FOXN3-AS1        0.005
                DNAH17-AS1       0.005
                RP11-404P21.5    0.008
                RP11-362F19.1    0.005
                RP11-179B2.2     0.017
                CTD-2184D3.7     0.005
                ERVK-28          0.000
                RP11-488C13.5    0.017
                AJ011932.1       0.000
                RP11-665C16.5    0.005
                RP1-90G24.10     0.008
                RP1-283K11.3     0.000
                RP11-486B10.3    0.008
  *HK2*         LINC01397        0.005
                TSPEAR-AS1       0.017
                AC083843.1       0.017
                AP001065.15      0.017
                MIR210HG         0.017
                MALAT1           0.003
                RP4-737E23.5     0.017
                AL591893.1       0.008
                LUCAT1           0.003
                RP11-359D14.3    0.008
                RP11-166D19.1    0.017
  *HIST1H2AI*   FOXN3-AS1        0.005
                DNAH17-AS1       0.005
                RP11-404P21.5    0.008
                RP11-362F19.1    0.005
                RP11-179B2.2     0.017
                CTD-2184D3.7     0.005
                ERVK-28          0.000
                RP11-488C13.5    0.017
                AJ011932.1       0.000
                RP11-665C16.5    0.005
                RP1-90G24.10     0.008
                RP1-283K11.3     0.000
                RP11-486B10.3    0.008
  *HIST1H2AE*   FOXN3-AS1        0.005
                DNAH17-AS1       0.005
                RP11-362F19.1    0.005
                RP11-449P15.2    0.017
                CTD-2184D3.7     0.005
                RP11-665C16.5    0.005
                RP11-826N14.1    0.008
                RP11-486B10.3    0.008
  *HIST3H2BB*   FOXN3-AS1        0.005
                DNAH17-AS1       0.005
                RP11-404P21.5    0.008
                RP11-362F19.1    0.005
                RP11-179B2.2     0.017
                CTD-2184D3.7     0.005
                ERVK-28          0.000
                RP11-488C13.5    0.017
                AJ011932.1       0.000
                RP11-665C16.5    0.005
                RP1-90G24.10     0.008
                RP1-283K11.3     0.000
                RP11-486B10.3    0.008

PPI, protein-protein interaction.

Enrichment Analyses for Targets of lncRNA Isolated From DEGs {#S3.SS4}
------------------------------------------------------------

To further reveal the regulatory role of lncRNA, functional enrichment analyses for the targets of lncRNAs were also performed. The up-regulated targets were significantly enriched in the GO-BP terms of cell response to hypoxia (*P* = 9.60 × 10^--10^), cellular response to decreased oxygen levels (*P* = 9.60 × 10^--10^), cellular response to oxygen levels (*P* = 1.57 × 10^--09^), glycolytic process (*P* = 2.56 × 10^--09^), and pyruvate metabolic process (*P* = 2.84 × 10^--09^); the down-regulated targets were predominately associated with the GO-BP terms of extracellular matrix organization (*P* = 2.79 × 10^--06^), extracellular structure organization (2.79 × 10^--06^), collagen catabolic process (*P* = 3.56 × 10^--05^), multicellular organismal catabolic process (*P* = 4.13 × 10^--05^), and extracellular matrix disassembly (*P* = 4.13 × 10^--05^) ([Table 4](#T4){ref-type="table"}). The KEGG enrichment results showed that the up-regulated DEGs were significantly enriched in the pathways of glycolysis/gluconeogenesis (*P* = 1.85 × 10^--07^), fructose and mannose metabolism (*P* = 7.44 × 10^--07^), and metabolic pathways (*P* = 0.0019); the down-regulated targets were significantly enriched in the pathways of systemic lupus erythematosus (*P* = 1.06 × 10^--15^), ECM-receptor interaction (*P* = 3.82 × 10^--06^), amoebiasis (*P* = 1.13 × 10^--05^), and focal adhesion (*P* = 4.91 × 10^--04^) ([Table 4](#T4){ref-type="table"}).

###### 

Functional enrichment analytical results for targets of lncRNAs.

  Terms                                          Count   *P* value         Genes
  ---------------------------------------------- ------- ----------------- ---------------------------------------------------------
  **A: Go functional enrichment**                                          
  ***Up-regulated targets***                                               
  Cellular response to hypoxia                   12      9.60 × 10^--10^   *NDRG1*, *EGLN3*, *FAM162A*, *HMOX1*, *PDK1, VEGFA*.
  Cellular response to decreased oxygen levels   12      9.60 × 10^--10^   *NDRG1*, *EGLN3*, *FAM162A*, *HMOX1*, *PDK1, VEGFA*.
  Cellular response to oxygen levels             12      1.57 × 10^--09^   *NDRG1*, *EGLN3*, *FAM162A*, *HMOX1*, *PDK1, VEGFA*.
  Glycolytic process                             10      2.56 × 10^--09^   *ENO2*, *ALDOC*, *HK2*, *LDHA*, *PFKFB3, PFKP*,...
  Pyruvate metabolic process                     11      2.84 × 10^--09^   *ENO2*, *ALDOC*, *HK2*, *LDHA*, *PDK1, PFKP*.
  ***Down-regulated targets***                                             
  Extracellular matrix organization              14      2.79 × 10^--06^   *COL1A1*, *COL2A1*, *COL3A1*, *COL26A1*, *THBS1*.
  Extracellular structure organization           14      2.79 × 10^--06^   *COL1A1*, *COL2A1*, *COL3A1*, *COL26A1*, *THBS1*.
  Collagen catabolic process                     7       3.56 × 10^--05^   *COL1A1*, *COL2A1*, *COL3A1*, *COL26A1*, *ADAMTS14*.
  Multicellular organismal catabolic process     7       4.13 × 10^--05^   *COL1A1*, *COL2A1*, *COL3A1*, *COL26A1*, *ADAMTS14*.
  Extracellular matrix disassembly               8       4.13 × 10^--05^   *COL1A1*, *COL2A1*, *COL3A1*, *COL26A1*, *LAMC2*.
                                                                           
  **B: KEGG functional enrichment**                                        
                                                                           
  ***Up-regulated targets***                                               
  Glycolysis/Gluconeogenesis                     8       1.85 × 10^--07^   *ALDOC*, *ENO2*, *HK2*, *HKDC1*, *LDHA*, *PFKP*.
  Fructose and mannose metabolism                6       7.44 × 10^--07^   *ALDOC*, *HK2, HKDC1*, *PFKFB3*, *PFKFB4*, *PFKP,...*
  Metabolic pathways                             19      0.0019            *AK4*, *ALDOC, DGKD*, *DGKE*, *ENO2, PFKP*.
  ***Down-regulated targets***                                             
  Systemic lupus erythematosus                   16      1.06 × 10^--15^   *HIST1H2AE*, *HIST1H2AI*, *HIST1H2BH*, *HIST2H4A*,...
  ECM-receptor interaction                       7       3.82 × 10^--06^   *COL1A1*, *COL2A1, COL3A1*, *COL5A3*, *THBS1*,.
  Amoebiasis                                     7       1.13 × 10^--05^   *CD14*, *COL1A1*, *COL2A1, COL3A1*, *COL5A3*, *LAMA4*.
  Focal adhesion                                 7       4.91 × 10^--04^   *COL1A1*, *COL2A1*, *COL3A1*, *COL5A3*, *LAMA4, THBS1*.

GO, gene ontology; BP, biological process; and KEGG, kyoto encyclopedia of genes and genomes.

The mRNA Expression of DEGs/DELs {#S3.SS5}
--------------------------------

According to the bio-informatics results, expression changes of several DEGs and DELs were validated using RT-PCR in HPASMCs. The validated results showed that expression levels of *PFKP*, miR-100HG, *RP11-166d19*, *VEGFA*, *LDHA*, and *AP001065.15* were significantly up-regulated, while expression levels of *RP11-568J2*, *HIST1H1B*, *HIST2H4A*, *TSPEAR-AS2*, *DYX1C1-CCPG*1, and *LINC00951* were significantly decreased in CoCl~2~-treated HPASMCs compared with the control groups, which were consistent with the findings based on the bioinformatics analyses ([Figure 5](#F5){ref-type="fig"}).

![Validation of differentially expressed genes using real-time PCR. Compared with the control group, \**P* \< 0.05, \*\**P* \< 0.01.](fgene-11-00232-g005){#F5}

The Protein Expression of PFKP, VEGFA, LDHA {#S3.SS6}
-------------------------------------------

The expression changes of *PFKP, VEGFA*, and *LDHA* at protein level were also determined by western blotting in HPASMCs ([Figure 6](#F6){ref-type="fig"}). The results showed that the protein expression of *PFKP, VEGFA*, and *LDHA* were significantly increased in HPASMCs after COCl~2~ treatment. The results were consistent with the bioinformatics analyses.

![The protein expression of PFKP, VEGFA, and LDHA determined by western blotting. Compared with the control group, ^∗∗^*P* \< 0.01.](fgene-11-00232-g006){#F6}

Discussion {#S4}
==========

Pulmonary arterial hypertension is considered a sub-population of PH, characterized by sustained pulmonary vascular resistance elevation that results in right heart failure and death ([@B29]; [@B2]). Overwhelming evidence has demonstrated that chronic hypoxia serves as a potential trigger for pulmonary vascular remodeling, and *HIF-1*α is reported to play a critical role during this process ([@B2]). Although numerous achievements have been acquired in exploring the underlying pathogenesis of PAH, the corresponding molecular mechanisms have not been deciphered. In this study, CoCl~2~ could significantly increase the expression of *HIF-1*α and proliferation of HPASMCs and decrease the apoptosis of HPASMCs even though there was no statistical difference. Moreover, 360 DEGs (178 up-regulated and 185 down-regulated genes) and 57 DELs (21 up-regulated and 36 lncRNAs) were screened in HPASMCs treated with CoCl~2~ compared with the control group. Interestingly, we found that *LDHA*, *PFKP*, and *VEGFA*, which were regarded as hub genes in PPI network, exhibited a strong relationship with miR-100HG and TSPEAR-AS2 in lncRNA-target network. Additionally, the functional enrichment analysis of these three genes revealed that they probably played pivotal roles in the cellular response to hypoxia and the regulation of glycolysis.

*LDHA*, lactate dehydrogenase A ([@B6]) has been reported to be a crucial regulator in glycolytic metabolism. Two earlier studies illuminated that an energy shift from mitochondrial oxidative phosphorylation to glycolytic metabolism was strongly associated with the progression of PH, which basically induced cell hyper-proliferation and inhibited apoptosis ([@B13]; [@B5]). Consistently, our results implied that there was a significant increase for the proliferation of HPASMCs after 200 μM CoCl~2~ treatment but not in apoptosis. Later, [@B26] elaborated the metabolic mechanisms of PAH and also emphasized that glycolysis was primarily responsible for the PAH occurrence and development. [@B45] argued that *LDHA* could dramatically enhance the activity of glycolysis in proliferating cells while *LDHA* knockdown retarded the glucose metabolism. In this work, we found that *LDHA* was significantly up-regulated in CoCl~2~-treated cells and remarkably enriched in glycolytic process, pyruvate metabolic process, and carbohydrate catabolic process. More notably, [@B46] investigated the expression of *LDHA* in monocrotaline-induced PHA rats and pointed out that *LDHA* was up-regulated, which was similar to our finding. Therefore, we speculated that *LDHA* might be involved in the PHA progression, presumably via mediating cell energy metabolism.

A huge amount of research has found that the vascular endothelial growth factor A (*VEGFA*) was closely correlated with the development of PH ([@B25]; [@B24]; [@B9]). [@B37] previously found that there was a higher level of *VEGFA* plasma compared with the controls based on the enzyme immunoassays, and stated that *VEGFA* could be regarded as a promising diagnostic maker for PH. Recently, [@B19] revealed that the expression levels of *HIF-1*α and *VEGFA* were significantly elevated in human pulmonary arterial endothelia cells (HPAECs) with hypoxia and the activation of *HIF-1*α*/VEGFA* axis acted as a potential driver for vascular remodeling contributing to PH, which was consistent with our results that *HIF-1*α and *VEGFA* levels were dramatically increased in hypoxia-induced HPASMCs. Additionally, our functional enrichment analysis indicated that *VEGFA* played essential roles in cellular response to oxygen levels. Taken together, our results provided support for the hypothesis that the initiation of *HIF-1*α*/VEGFA* axis was implicated with HAP under hypoxia exposure.

Phosphofructokinase (*PFKP*) gene was involved with various cell activities and glucose metabolism by targeting to multiple cell receptors and was reported to be another prominent regulator in the progression of HP ([@B1]). Here, we found that this gene was up-regulated in HPASMCs and mainly participated in energy metabolism pathways such as fructose and mannose metabolism. [@B4] suggested that the expression of *PFKP* was increased in human PAH cells, which was in accordance with our finding. And they underscored that peroxisome proliferator-activated receptor gamma (PPARγ) could bind to *PFKP* to regulate the proliferation and metabolism of PH cells. Interestingly, *LDHA*, *PFKP*, and *VEGFA* all had a close correlation with miR-100HG and *TSPEAR-AS2* in our analysis. Unfortunately, few relevant investigations have been undertaken to explore the effect of the interaction between these genes and corresponding mRNAs on PAH occurrence and development. Therefore, the precise underlying mechanisms still need to be further elucidated.

In the current work, although we have identified several crucial gene signatures in PAH progression on the basis of bioinformatics methods, there are still limitations in our investigation. Firstly, the purity of HPASMCs should be determined before CoCl~2~ treatment to obtain more comprehensive results. Secondly, related animal experiments are required to confirm our findings even though we have verified significant genes by qPCR. Meanwhile, the exhaustive examinations containing a larger sample size was also needed, and the HPASMC RNA-seq data under different treatment should be further investigated. In addition, the detailed regulatory mechanisms associated with our confirmed genes remains to be deciphered.

Conclusion {#S5}
==========

In conclusion, CoCl~2~-induced hypoxia could significantly increase *HIF-1*α level and the proliferation of HPASMCs but decrease the apoptosis. Meanwhile, the expression levels of *VEGFA*, *LDHA*, and *PFKP* were dramatically enhanced in hypoxia-induced HPASMCs, preferentially associated with glycolytic process and exhibited a close correlation with miR-100H*G* and *TSPEAR-AS*2, which were considered as pivotal players in PAH development. However, animal experimental verification and a comprehensive bioinformatics analysis will need to be performed in future.
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